DermTech stock surges after it announces contract with Hawaii Blues plan for melanoma test
- Molecular diagnostic company DermTech (NASDAQ:DMTK) shares jumps 7.6% premarket on Wednesday after it signs a contract with a Blues plan in Hawaii.
- In addition to a favorable coverage policy, the contract enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the nearly 800,000 members.
- The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value.
- "The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. After reviewing our portfolio of clinical and health economic data, payers are recognizing the value of our test and resulting benefits to their membership, network providers and health plans."
More on DermTech: